0.1.0 - ci-build
HIVFHIRIG, published by intellisoftkenya. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/IntelliSOFT-Consulting/HIV-FHIR-IG/ and changes regularly. See the Directory of published versions
This section details indicators and performance metrics that would be aggregated from core data elements identified in Component 5.
| Indicator Code | Indicator Name | Description | Numerator | Denominator | Disaggregation | Reference | ||
|---|---|---|---|---|---|---|---|---|
| Definition | Computation | Definition | Computation | |||||
| HIV.IND.1 | TX-NEW | Number of adults and children newly enrolled in antiretroviral therapy - ART | Number of adults and children newly enrolled on antiretroviral therapy (ART). | count the number of adults and children who are newly enrolled in ART in the reporting period. Pregnant women with HIV who are eligible for and are newly receiving antiretroviral drugs for their own treatment are included in TX_NEW | N/A | N/A |
Age
Sex Location Key population Breastfeeding status at ART initiation |
PEPFAR Fiscal Year 2023 Monitoring, Evaluation, and Reporting (MER) Indicators |
| HIV.IND.2 | TX-RTT | Number of ART patients who successfully restarted treatment after interruption | Number of ART clients who experienced an interruption in treatment (IIT) during any previous reporting period, who successfully restarted ARVs within the reporting period and remained on treatment until the end of the reporting period. | Count the number of individuals who were previously on ART who restarted ARVs after being off treatment for ≥28 days (and therefore experienced IIT) | N/A | N/A |
Age
Sex Location Key population Duration of treatment interruption before returning to treatment |
PEPFAR Fiscal Year 2023 Monitoring, Evaluation, and Reporting (MER) Indicators |
| HIV.IND.3 | TX-PVLS | Percentage of ART clients with a suppressed viral load (VL) result ( < 1000 copies / ml) documented in the medical or laboratory records/laboratory information systems (LIS) within the past 12 months | The number of ART clients with suppressed VL results (<1,000 copies /ml) documented in the medical or laboratory records within the past 12 months | Count the number of ART clients with suppressed VL results (<1,000 copies/ml) documented in the medical or laboratory records/ | Number of ART clients with a VL result documented in the medical or laboratory re | Count the number of ART clients with VL results documented in the medical or laboratory records |
Age
Sex Location Key population |
PEPFAR Fiscal Year 2023 Monitoring, Evaluation, and Reporting (MER) Indicators |
| HIV.IND.4 | TX-ML | Number of ART clients (who were on ART at the beginning of the quarterly reporting period or initiated treatment during the reporting period) and then had no clinical contact since their last expected contact. | Number of ART clients (currently on ART or newly initiating ART) with no clinical contact or ARV pick-up for greater than 28 days since their last expected clinical contact or ARV pick-up | Count the number of ART clients (currently on ART or newly initiating ART) with no clinical contact or ARV pick-up for greater than 28 days since their last expected clinical contact or ARV pick-up | N/A | N/A |
Age
Sex Location Key population |
PEPFAR Fiscal Year 2023 Monitoring, Evaluation, and Reporting (MER) Indicators |
| HIV.IND.5 | HTS-TST | Number of individuals who received HIV Testing Services and received their test results | Number of individuals who received HIV Testing Services and received their test results | Count the number of individuals who received HIV Testing Services and received their test results | N/A | N/A |
Age
Sex Location Key population Service mortality |
PEPFAR Fiscal Year 2023 Monitoring, Evaluation, and Reporting (MER) Indicators |